TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012
TCL Archive Dept. of Defense opens program announcements for prostate cancer research. December 10, 2004
TCL Archive After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant June 11, 2014